Hereditary Transthyretin Amyloidosis Market Set to Expand Significantly in Terms of Value and CAGR by 2029
Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Current Size and Annual Growth Rate of the Hereditary Transthyretin Amyloidosis Market?
The hereditary transthyretin amyloidosis market size has grown strongly in recent years. It will grow from $1.36 billion in 2024 to $1.49 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to the rising incidence of this disorder, an increase in research and development activities, an increasing number of cardiac amyloidosis cases, growing disease awareness, and increasing healthcare infrastructure.
The hereditary transthyretin amyloidosis market size is expected to see strong growth in the next few years. It will grow to " $2.09 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to a growing geriatric population, rising disposable incomes, increasing incidence of hereditary transthyretin amyloidosis, a rise in the development of new drugs, and a rise in genetic testing. Major trends in the forecast period include advanced treatment products, advancements in diagnostic techniques, advancements in drug development, demand for effective therapies, and advancements in medical technology.
Get your free report sample today:
Which Core Market Drivers Are Influencing the Development of the Hereditary Transthyretin Amyloidosis Market?
The growing geriatric population is expected to propel the growth of the hereditary transthyretin amyloidosis market going forward. The geriatric population refers to individuals aged 65 and older, often requiring specialized healthcare and support due to aging. The geriatric population is growing due to increasing life expectancy driven by advancements in healthcare and living conditions. Hereditary transthyretin amyloidosis (hATTR) significantly impacts the geriatric population by causing progressive neuropathy and cardiomyopathy, leading to increased morbidity in aging individuals. For instance, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Therefore, the growing geriatric population is driving the growth of the hereditary transthyretin amyloidosis market.
Which Market Segment Offers the Most Significant Growth Opportunities in the Hereditary Transthyretin Amyloidosis Market?
The hereditary transthyretin amyloidosismarket covered in this report is segmented –
1) By Type: Oral; Subcutaneous Injection; Other Types
2) By Drug Class: RNAi Agents (Patisiran); Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
4) By Application: Hospital; Clinic; Other Applications
Subsegments:
1) By Oral: Tafamidis; Diflunisal; Experimental Oral Therapies
2) By Subcutaneous Injection: Patisiran; Inotersen; Vutrisiran
3) By Other Types: Intravenous Therapies; Gene Silencing Therapies; CRISPR-Based Therapies
What New Market Trends Are Emerging in the Hereditary Transthyretin Amyloidosis Market?
Major companies operating in the hereditary transthyretin amyloidosis market are developing innovative therapeutics, such as RNAi therapeutics, to target and reduce the production of transthyretin (TTR) protein. RNAi therapeutics are a class of drugs that use RNA interference technology to silence specific genes, thereby reducing the production of disease-causing proteins. For instance, in October 2024, Alnylam Pharmaceuticals, Inc., a US-based biopharmaceutical company, submitted a supplemental new drug application (sNDA) to the US FDA for Vutrisiran (AMVUTTRA) as a treatment for transthyretin amyloidosis with cardiomyopathy. This submission underscores its innovative RNAi therapeutic approach, designed to target and reduce transthyretin (TTR) protein, a key factor in disease progression. Vutrisiran’s subcutaneous administration offers a more convenient and patient-friendly dosing regimen compared to traditional intravenous treatments, positioning it as a potentially transformative option for individuals with this serious condition.
Who Are the Top Performers and Innovators in the Hereditary Transthyretin Amyloidosis Market?
Major companies operating in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, Autotac Bio Inc.
Get the detailed hereditary transthyretin amyloidosis market report today
Which Regional Markets Are Likely to See the Most Significant Expansion in the Coming Years?
North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment